Literature DB >> 18786654

Visceral analgesics: drugs with a great potential in functional disorders?

Sylvie Bradesi1, Jeremy Herman, Emeran A Mayer.   

Abstract

Irritable bowel syndrome remains an incompletely understood, common syndrome with significant unmet medical needs. In IBS patients, abdominal pain is a primary factor related to quality of life impairment, symptom severity and health care utilization, and chronic visceral hyperalgesia has been identified as an important aspect of IBS pathophysiology. However, the development of therapies aimed at reducing this hyperalgesia (visceral analgesics) has been only partially successful despite preclinical evidence supporting the potential usefulness of several preclinical compounds aimed at peripheral as well as central targets.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18786654      PMCID： PMC2651816          DOI： 10.1016/j.coph.2008.08.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  64 in total

1.  Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.

Authors:  Pankaj Jay Pasricha
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

2.  Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain.

Authors:  Liza Leventhal; Valerie Smith; Geoffrey Hornby; Terrance H Andree; Michael R Brandt; Kathryn E Rogers
Journal:  J Pharmacol Exp Ther       Date:  2006-12-01       Impact factor: 4.030

3.  Role for protease activity in visceral pain in irritable bowel syndrome.

Authors:  Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

Review 4.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.

Authors:  E M M Quigley; B Flourie
Journal:  Neurogastroenterol Motil       Date:  2007-03       Impact factor: 3.598

5.  Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors.

Authors:  Christel Rousseaux; Xavier Thuru; Agathe Gelot; Nicolas Barnich; Christel Neut; Laurent Dubuquoy; Caroline Dubuquoy; Emilie Merour; Karen Geboes; Mathias Chamaillard; Arthur Ouwehand; Greg Leyer; Didier Carcano; Jean-Frédéric Colombel; Denis Ardid; Pierre Desreumaux
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

6.  Transient receptor potential vanilloid-4 has a major role in visceral hypersensitivity symptoms.

Authors:  Nicolas Cenac; Christophe Altier; Kevin Chapman; Wolfgang Liedtke; Gerald Zamponi; Nathalie Vergnolle
Journal:  Gastroenterology       Date:  2008-05-10       Impact factor: 22.682

Review 7.  Mechanisms of hypersensitivity in IBS and functional disorders.

Authors:  F Azpiroz; M Bouin; M Camilleri; E A Mayer; P Poitras; J Serra; R C Spiller
Journal:  Neurogastroenterol Motil       Date:  2007-01       Impact factor: 3.598

8.  Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome.

Authors:  J Tayama; Y Sagami; Y Shimada; M Hongo; S Fukudo
Journal:  Neurogastroenterol Motil       Date:  2007-06       Impact factor: 3.598

9.  Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

Authors:  D Guyonnet; O Chassany; P Ducrotte; C Picard; M Mouret; C-H Mercier; C Matuchansky
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

10.  Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system.

Authors:  Selim Cellek; Ramkumar Thangiah; Anna K Bassil; Colin A Campbell; Karen M Gray; Jennifer L Stretton; Olutunde Lalude; Shanmugam Vivekanandan; Alan Wheeldon; Wendy J Winchester; Gareth J Sanger; Michael Schemann; Kevin Lee
Journal:  Gastroenterology       Date:  2007-05-10       Impact factor: 22.682
View more
  9 in total

1.  NaV1.1 inhibition can reduce visceral hypersensitivity.

Authors:  Juan Salvatierra; Joel Castro; Andelain Erickson; Qian Li; Joao Braz; John Gilchrist; Luke Grundy; Grigori Y Rychkov; Annemie Deiteren; Rana Rais; Glenn F King; Barbara S Slusher; Allan Basbaum; Pankaj J Pasricha; Stuart M Brierley; Frank Bosmans
Journal:  JCI Insight       Date:  2018-06-07

2.  P2X₇ receptor of rat dorsal root ganglia is involved in the effect of moxibustion on visceral hyperalgesia.

Authors:  Shuangmei Liu; Qingming Shi; Qicheng Zhu; Ting Zou; Guilin Li; An Huang; Bing Wu; Lichao Peng; Miaomiao Song; Qin Wu; Qiuyu Xie; Weijian Lin; Wei Xie; Shiyao Wen; Zhedong Zhang; Qiulan Lv; Lifang Zou; Xi Zhang; Mofeng Ying; Guodong Li; Shangdong Liang
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

3.  The κ-opioid receptor agonist U-50488 blocks Ca2+ channels in a voltage- and G protein-independent manner in sensory neurons.

Authors:  Bassil Hassan; Victor Ruiz-Velasco
Journal:  Reg Anesth Pain Med       Date:  2013 Jan-Feb       Impact factor: 6.288

Review 4.  Neuroanatomy of lower gastrointestinal pain disorders.

Authors:  Wim Vermeulen; Joris G De Man; Paul A Pelckmans; Benedicte Y De Winter
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

5.  Comparative effects of α2δ-1 ligands in mouse models of colonic hypersensitivity.

Authors:  Mathieu Meleine; Ludivine Boudieu; Agathe Gelot; Emilie Muller; Amandine Lashermes; Julien Matricon; Celine Silberberg; Vassilia Theodorou; Alain Eschalier; Denis Ardid; Frederic A Carvalho
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

6.  Warming Moxibustion Relieves Chronic Visceral Hyperalgesia in Rats: Relations to Spinal Dynorphin and Orphanin-FQ System.

Authors:  Li Qi; Hui-Rong Liu; Tao Yi; Lu-Yi Wu; Xi-Ru Liu; Chen Zhao; Yin Shi; Xiao-Peng Ma; Huan-Gan Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-16       Impact factor: 2.629

Review 7.  DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia.

Authors:  Yong Sam Kwon; Miwon Son
Journal:  Biomol Ther (Seoul)       Date:  2013-05-30       Impact factor: 4.634

Review 8.  Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.

Authors:  Rachel D Moloney; Siobhain M O'Mahony; Timothy G Dinan; John F Cryan
Journal:  Front Psychiatry       Date:  2015-02-16       Impact factor: 4.157

Review 9.  Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2018-03-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.